Gland Pharma Limited (BOM:543245)

Market Cap	323.70B
Revenue (ttm)	57.27B
Net Income (ttm)	7.70B
Shares Out	n/a
EPS (ttm)	46.75
PE Ratio	42.03
Forward PE	32.04
Dividend	18.00 (0.91%)
Ex-Dividend Date	Aug 14, 2025

Volume	4,519
Average Volume	11,781
Open	1,977.20
Previous Close	1,981.05
Day's Range	1,933.85 - 2,009.40
52-Week Range	1,200.00 - 2,220.95
Beta	n/a
RSI	53.01
Earnings Date	Aug 1, 2025

About Hess Corporation

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,286
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In 2024, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.

Financial numbers in BGN